Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 12, 2008, Pages 4780-4786

  Rossi, Brooke ^b   Sukalich, Sara ^a   Droz, Jennifer ^a   Griffin, Adam ^b   Cook, Stephen ^a   Blumkin, Aaron ^a   Guzick, David S ^a   Hoeger, Kathleen M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; TESTOSTERONE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; OVARY; OVARY POLYCYSTIC DISEASE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; WAIST CIRCUMFERENCE;

EID: 57349132982     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1198     Document Type: Article

References (39)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19-25
2. Essah PA, Wickham EP, Nestler JE 2007 The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 50:205-225
3. Cook S, Auinger P, Li C, Ford ES 2008 Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. J Pediatr 152:165-170
4. Coviello AD, Legro RS, Dunaif A 2006 Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91:492-497
5. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL 2006 Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab 91:1275-1283
6. Ford ES 2004 The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II mortality study. Atherosclerosis 173:309-314
7. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V 2002 Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 165:285-292
8. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA 1998 Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51:415-422
9. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L 1995 Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821-826
10. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH 2003 Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 157:821-827
11. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F, American Heart Association, National Heart, Lung, and Blood Institute 2005 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735-2752
12. Zimmet P, Alberti KGMM, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S; IDF Consensus Group 2007 The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 8:299-306
13. Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S, on behalf of the International Diabetes Federation Task Force on Epidemiology and Prevention of Diabetes 2007 The metabolic syndrome in children and adolescents. Lancet 369:2059-2061
14. Alberti G, Zimmett P, Shaw J 2005 The metabolic syndrome - a new worldwide definition. Lancet 366:1059-1062
15. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749
16. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM 2006 Prevalence of overweight and obesity in the united states, 1999-2004. JAMA 295:1549-1555
17. Yildiz BO, Knochenhauer ES, Azziz R 2008 Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 93:162-168
18. Li C, Ford ES, Mokdad AH, Cook S 2006 Recent trends in waist circumference and waist-height ratio among US children and adolescents. Pediatrics 118:e1390-e1398
19. Chang RJ, Coffler MS 2007 Polycystic ovary syndrome: early detection in the adolescent. Clin Obstet Gynecol 50:178-187
20. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G, Rini G 2007 Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92:2500-2505
21. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B 2005 Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 90:6014-6021
22. Kirchengast S, Huber J 2001 Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16:1255-1260
23. Yildirim B, Sabir N, Kaleli B 2003 Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 79:1358-1364
24. Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, McCarthy MI 2008 Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab 93:999-1004
25. Cussons AJ, Stuckey BG, Watts GF 2006 Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 185:227-239
26. Orio Jr F, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A 2004 The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89:3696-3701
27. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R 2003 Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 18:721-727
28. Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Toruner F, Cakir N, Arslan M 2005 The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 20:3333-3340
29. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A 2007 Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 92:4609-4614
30. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774-800
31. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J 2000 Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 15:785-789
32. Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS 2007 Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 49:1442-1447
33. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, PCOS/Troglitazone Study Group 2006 Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91:48-53
34. Arslanian SA, Lewy VD, Danadian K 2001 Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 86:66-71
35. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG 1998 The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 69:236-241
36. Tarkun I, Canturk Z, Arslan BC, Turemen E, Tarkun P 2004 The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 51:467-472
37. Tsikouris JP, Suarez JA, Meyerrose GE 2002 Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 42:1187-1199
38. Morrison JA, Friedman LA, Gray-McGuire C 2007 Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinic Follow-up Study. Pediatrics 120:340-345
39. Morrison JA, Friedman LA, Wang P, Glueck CJ 2008 Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr 152:201-206